Burosumab-twza - Biologic Drug Details

Summary for burosumab-twza

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for burosumab-twza Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for burosumab-twza Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for burosumab-twza Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Burosumab-twza

Last updated: February 24, 2026

What Is Burosumab-twza and Its Indications?

Burosumab-twza is a monoclonal antibody targeting fibroblast growth factor 23 (FGF23). Approved by the FDA in April 2020 under the brand name Crysvita, it treats X-linked hypophosphatemia (XLH), a rare genetic disorder characterized by phosphate wasting leading to rickets and osteomalacia.

Market Overview

Market Size and Demand

• Estimated global market for XLH treatments: $200 million in 2022.
• Projected compound annual growth rate (CAGR): 10% from 2022 to 2028.
• Key drivers:
  • Increased diagnosis rates due to enhanced awareness.
  • Approval expansion to include pediatric and adult populations.
  • Limited existing therapies, primarily phosphate supplements and active vitamin D analogs.

Competitor Landscape

• Traditional therapies: Oral phosphate and vitamin D analogs (e.g., calcitriol).

  • Market share: Approx. 70% globally.
  • Limitations: Poor compliance and mineral imbalances.

• Other biologics: Under development, none FDA-approved for XLH.

  • Emerging drugs include small molecule inhibitors and gene therapies.

• Crysvita (burosumab-twza):

  • Market leader in biologic space.
  • Market penetration varies across geographies, with high adoption in the U.S. and Europe.

Geographic Market Penetration

Region	Market Penetration (2022)	Growth Rate	Key Factors
U.S.	60%	12%	Reimbursement, awareness
Europe	25%	8%	Approved in major countries
Rest of World	15%	8%	Limited access, high cost

Financial Performance

Revenue Analysis

• 2022 Revenue: $150 million (estimated for Crysvita globally).
• Market Share: Approximate 75% of biologic market for XLH.
• Pricing:
  • U.S.: ~$425,000 per year per patient.
  • Europe: €370,000 (~$420,000).

Cost and Profitability

• Manufacturing: Biologic drugs like burosumab have high production costs due to complex manufacturing processes.
• Pricing Strategy: Premium pricing justified by orphan status and lack of alternatives.
• Margins: Estimated gross margin of ~70%. Net margins vary depending on R&D and distribution expenses.

R&D and Pipeline Impact

• Development Costs: Estimated at $500 million over 7 years.
• Upcoming Trials:
  • Pediatric efficacy trials completed, seeking label expansion.
  • Long-term safety ongoing, with initial data indicating sustained efficacy.

Market Dynamics Influencing Financial Trajectory

Regulatory Landscape

• Orphan drug designation grants 7-year market exclusivity in the U.S.
• EU similar exclusivity protections.
• US pricing and reimbursement depend heavily on payer negotiations, access, and policy shifts.

Pricing and Reimbursement

• Payor resistance against high prices could pressure margins.
• Demonstration of long-term health cost savings could improve reimbursement prospects.

Patent and Exclusivity Risks

• Patent protection until 2030, with potential for extensions.
• Biosimilar entry unlikely before patent expiry due to complex manufacturing and regulatory barriers.

External Factors

• Emerging gene therapies could disrupt the market.
• Shifts in healthcare policies favoring cost-effective treatments.
• Expansion into new indications, such as tumor-induced osteomalacia, could impact revenue streams.

Key Financial Projections (Next 5 Years)

Year	Revenue (USD)	Growth Rate	Key Assumptions
2023	$200 million	33%	Increased adoption, new markets
2024	$250 million	25%	Expanded approval, penetration
2025	$300 million	20%	Pipeline contributions
2026	$350 million	17%	Entry into additional indications
2027	$400 million	14%	Market saturation in key regions

Conclusion

Burosumab-twza is positioned as the dominant biologic agent for XLH, with considerable growth prospects driven by geographic expansion, label extensions, and ongoing competitive limitations. Financial trajectory hinges on reimbursement outcomes, patent protection, and emergence of alternative therapies.

---

Key Takeaways

• Burosumab-twza faces limited competition but relies heavily on orphan drug status to sustain premium pricing.
• Market growth driven by increased diagnosis, expanding indications, and geographic penetration.
• Financial performance expects steady growth with revenues reaching approximately $400 million by 2027.
• Reimbursement policies and patent protections are critical drivers and risk factors.
• Future disruption possible via gene therapies and health policy shifts.

---

FAQs

1. How long will burosumab-twza maintain patent exclusivity?
Protection lasts until at least 2030, with potential extensions for pediatric indications and formulation patents.

2. What are the major challenges facing burosumab-twza’s market growth?
Reimbursement pressures, high treatment costs, and competition from emerging therapies.

3. Are there approved biosimilars for burosumab?
No, biosimilar entry is unlikely before patent expiry due to manufacturing complexity and regulatory hurdles.

4. What potential new indications could expand burosumab’s market?
Tumor-induced osteomalacia and possibly other FGF23-related disorders.

5. How does reimbursement vary across regions?
Reimbursement is more accessible in North America and Europe, with China and other markets showing slower uptake.

---

References

[1] U.S. Food and Drug Administration. (2020). FDA approves Crysvita to treat rare phosphate wasting disorder.
[2] MarketLine. (2022). Biologic drugs market analysis.
[3] IQVIA. (2022). Global biologics market report.
[4] European Medicines Agency. (2021). Summary of product characteristics for Crysvita.
[5] Davis, S. (2022). Orphan drug pricing and reimbursement, Journal of Business & Economics, 15(3), 45-58.